ESR1 and prostate carcinoma: Additionally, the proliferative effects of E2 in MCF-7/BOS cells (used as positive control) were completely abrogated by the selective ERα antagonist MPP in MCF-7/BOS cells, as observed previously in normal mammary epithelial cells, PC3 prostate cancer cells, and MCF-7 breast cancer cells [33–35].